MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

30.21
+0.11
+0.37%
After Hours: 30.21 0 0.00% 16:46 02/25 EST
OPEN
29.78
PREV CLOSE
30.10
HIGH
31.60
LOW
28.99
VOLUME
955.20K
TURNOVER
--
52 WEEK HIGH
31.60
52 WEEK LOW
9.24
MARKET CAP
2.27B
P/E (TTM)
-10.5199
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Direct-to-Consumer Genetic Testing: Global Markets and Technologies
Feb 25, 2021 (Heraldkeepers) -- COMTEX_381728872/2582/2021-02-25T12:29:15 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 11h ago
Breast Cancer Liquid Biopsy Market Global Forecasts to 2022 by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison, Competitive Landscape
Japan, Japan, Thu, 25 Feb 2021 11:25:26 / Comserve Inc. / -- Some of the major market players in the breast cancer liquid biopsy market are QIAGEN N.V....
Comserve · 12h ago
Breast Cancer Diagnostics Market Research Report by Type, by Technique, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19
New York, Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 13h ago
Next Generation Cancer Diagnostics: Technologies and Global Markets
Feb 25, 2021 (Heraldkeepers) -- COMTEX_381718272/2582/2021-02-25T09:41:34 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 14h ago
Rare Disease Diagnostics: Technologies and Global Markets
Feb 25, 2021 (Heraldkeepers) -- COMTEX_381716033/2582/2021-02-25T08:59:37 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 14h ago
Companion Diagnostics Market Size, Share, Growth, Research and Forecast 2020-2026
Market Insight Reports · 18h ago
Slone Partners Places Mark Capone as Non-Executive Board Member at Abcam
, /PRNewswire-PRWeb/ -- , a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of as a Non-Executive Board Member at , a global life science company that provides precise tools and sol...
PR Newswire - PRF · 19h ago
Global Pancreatic Cancer Diagnostic Market 2020 Industry Chain structure, Market Competition, SWOT Analysis Report by 2025
CDN Newswire · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYGN. Analyze the recent business situations of Myriad Genetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYGN stock price target is 26.00 with a high estimate of 34.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 355
Institutional Holdings: 87.69M
% Owned: 116.59%
Shares Outstanding: 75.21M
TypeInstitutionsShares
Increased
58
7.42M
New
48
-490.41K
Decreased
65
5.24M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.55%
Healthcare Equipment & Supplies
-1.74%
Key Executives
Chairman/Independent Director
S. Louise Phanstiel
President/Chief Executive Officer/Director
Paul Diaz
Chief Financial Officer/Executive Vice President/Treasurer
R. Bryan Riggsbee
Corporate Executive
Nicole Lambert
Corporate Executive
Mark Verratti
Corporate Executive
Faith Zaslavsky
Executive Vice President/General Counsel/Secretary
Benjamin Jackson
Executive Vice President/Director of Human Resources
Jayne Hart
Executive Vice President
Paul Parkinson
Senior Vice President
Maggie Ancona
Senior Vice President
Edward Gala
Other
Mark Pollack
Senior Vice President
David Hammer
Independent Director
Heinrich Dreismann
Senior Vice President
Chris Williamson
Chief Technology Officer
Kevin Haas
Chief Scientific Officer
Jerry Lanchbury
Vice President
Justin Hunter
Vice President
Karen Renner
Vice President - Business Development
Jackie Zou
Independent Director
Heiner Dreismann
Independent Director
Rashmi Kumar
Independent Director
Dennis Langer
Independent Director
Lee Newcomer
Independent Director
Colleen Reitan
Independent Director
Daniel Skovronsky
Independent Director
Daniel Spiegelman
  • Dividends
  • Splits
  • Insider Activity
No Data
About MYGN
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Webull offers kinds of Myriad Genetics, Inc. stock information, including NASDAQ:MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYGN stock methods without spending real money on the virtual paper trading platform.